Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$46.6B
15,416M shares
52-week range
$2.10 – $3.45
69% from low
Exchange
NYSE
ADRC
P/S (TTM)
0.5
EV / FCF (TTM)
1.4
Ambev is the largest brewer in Latin America and the Caribbean and is Anheuser-Busch InBev's subsidiary in the region. It produces, distributes, and sells beer and PepsiCo products in Brazil and other Latin American countries and owns Argentina's largest brewer, Quinsa. Ambev was formed in 1999 through the merger of Brazil's two largest beverage companies, Brahma and Antarctica. In 2004, Ambev combined with Canadian brewer Labatt, giving AB InBev a controlling interest of 62%.
www.ambev.com.brNo one on the platform currently holds ABEV.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 27,354,300 | $79.9M |
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-09-23 | $0.0140 | 2027-01-11 |
| 2026-06-24 | $0.0092 | 2027-01-11 |
| 2025-12-22 | $0.0833 | 2026-01-09 |
| 2025-12-22 | $0.0145 | 2026-04-16 |
| 2025-08-11 | $0.0240 | 2025-10-14 |
| 2025-05-19 | $0.0236 | 2025-07-17 |
| 2025-03-18 | $0.0224 | 2025-04-14 |
| 2024-12-23 | $0.0397 | 2025-01-09 |
| 2024-12-23 | $0.0687 | 2025-01-17 |
| 2023-12-22 | $0.1510 | 2024-01-05 |
No one on the platform has traded ABEV yet.
| Execution date | Ratio |
|---|---|
| 2013-11-11 | 5-for-1 |
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 24.5% | 25.0% | 27.0% | — | — | — |
| Rev. Growth % | -1.4% | 8.6% | ||||
| Profit Margin % | 17.6% | 17.5% | 19.4% | |||
| Free Cash Flow Margin % | 22.5% | 21.7% | 23.7% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is +27.0% on the P/E track.
At today's price, your expected annual return is +29.6% on the P/E track.
At today's price, your expected annual return is +32.4% on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $91.4B | +1.1% | $1.05 | $1.00–$1.15 | 2.9× | 5 |
| 2027 | $95.9B | +4.9% | $1.11 | $1.05–$1.21 | 2.7× | 4 |
| 2028 | $101.5B | +5.8% | $1.20 | $1.16–$1.27 | 2.5× | 2 |
| 2029 | $106.9B | +5.3% | $1.32 | $1.27–$1.39 | 2.3× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 7 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-30 | $0.04 | $0.04 | +0.0% |
| 2026-05-05 | $0.05 | $0.05 | +0.0% |
| 2026-02-12 | $0.05 | $0.05 | +0.0% |
| 2025-10-30 | $0.04 | $0.04 | +0.0% |
| 2025-07-31 | $0.03 | $0.03 | +0.0% |
| 2025-05-08 | $0.04 | $0.04 | +0.0% |
| 2025-02-26 | $0.05 | $0.05 | +0.0% |
| 2024-10-31 | $0.04 |
| $0.04 |
| -9.9% |
| $27.7B |
| — |
| KDPKeurig Dr Pepper Inc. | $31.58 | +0.61% | $43.0B | — |
| KMBKimberly-Clark Corporation | $99.09 | +0.96% | $32.9B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$ABEV Share Price: $3.05 Contract Selected: Apr 16, 2027 $2.5 Calls Buy Zone: $0.50 – $0.61 Target Zone: $0.85 – $1.04 Potential Upside: 62% ROI Time to Expiration: 212 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗$ABEV Share Price: $3.04 Contract Selected: Apr 16, 2027 $2.5 Calls Buy Zone: $0.47 – $0.58 Target Zone: $0.83 – $1.02 Potential Upside: 68% ROI Time to Expiration: 217 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗$ABEV Share Price: $3.02 Contract Selected: Apr 16, 2027 $2.5 Calls Buy Zone: $0.47 – $0.58 Target Zone: $0.81 – $0.99 Potential Upside: 64% ROI Time to Expiration: 220 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗$ABEV Share Price: $3.03 Contract Selected: Apr 16, 2027 $2.5 Calls Buy Zone: $0.47 – $0.58 Target Zone: $0.81 – $0.99 Potential Upside: 63% ROI Time to Expiration: 223 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗$ABEV Share Price: $3.04 Contract Selected: Apr 16, 2027 $2.5 Calls Buy Zone: $0.17 – $0.21 Target Zone: $0.32 – $0.39 Potential Upside: 76% ROI Time to Expiration: 224 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗
$ABEV Share Price: $2.89 Contract Selected: Apr 16, 2027 $2.5 Calls Buy Zone: $0.30 – $0.37 Target Zone: $0.49 – $0.60 Potential Upside: 57% ROI Time to Expiration: 226 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗$ABEV Share Price: $2.87 Contract Selected: Apr 16, 2027 $2.5 Calls Buy Zone: $0.38 – $0.47 Target Zone: $0.70 – $0.86 Potential Upside: 74% ROI Time to Expiration: 227 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗
$ABEV coiling up near recent range highs, volume drying up on the pullbacks. Watching how it reacts at resistance here. Bulls need a clean break to shift momentum. Patience mode until it shows its hand.
View on StockTwits ↗
$ABEV Check out Longeveron! Phase 1 - All 10 babies were alive after 1 year with no heart transplant, standard of care, survival is 70-80%...follow up of 10 babies after 5 years all are alive with no heart transplant....SOC is 3 heart surgeries....treatment is SOC (3 heart surgeries) + the drug (laromestrocel) given after 2nd heart surgery LGVN fully diluted market cap $40 million - $2 billion annual potential revenues (only US and Europe (untapped)) times a p/s of 8 -> $16 billion market cap, for only HLHS (unmet medical need...Hypoplastic Left Heart Syndrome...HLHS phase 2 results September 2026)...40 babies after 1 year (20:20) HLHS program may be eligible for PRV (priority review voucher) upon BLA approval (valued between $150-200 million) Incredible phase 2 Alzheimer’s results, granted RMAT fast-track - in talks with potential partners for phase 3 50 patents 60 patents pending
View on StockTwits ↗
$ABEV Great potential $1.88 near term potential. Going into Wednesday. 👀
View on StockTwits ↗
$ABEV The two new ISO-7 rooms are going to drastically increase RMTG output capacity which means they can fill larger and more frequent orders that increase in fulfillment volume is going to directly correlate with a higher top line revenue number for Q2
View on StockTwits ↗
$DEO $CCEP $AMP $ABEV $VTR Diageo leads premium beverages, Coca-Cola Europacific Partners expands global distribution, Ameriprise strengthens wealth management, Ambev dominates Latin American beverages, and Ventas benefits from healthcare real estate.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.